Department of Surgery, College of Medicine, King Faisal University, Al-Ahsa City, Eastern Province, Saudi Arabia.
Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, Korea.
Breast Cancer Res Treat. 2021 Jun;187(2):447-454. doi: 10.1007/s10549-021-06134-6. Epub 2021 Feb 18.
The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.
We retrospectively reviewed 594 patients diagnosed with stage I-III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.
At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(-)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(-) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(-) group and 93% in the p53(+) group (p = 0.008).
High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.
本研究旨在通过分析激素受体（HR）阳性和人表皮生长因子受体 2（HER2）阴性乳腺癌患者中 p53 的表达，确定新辅助化疗（NAC）的疗效是否可以预测。
我们回顾性分析了 2008 年至 2014 年期间在 Asan 医疗中心接受 NAC 治疗的 594 例 I-III 期 HR 阳性、HER2 阴性乳腺癌患者。评估了 p53 的表达，并比较了各组之间的总生存期（OS）和乳腺癌特异性生存期（BCSS）。
在中位随访 69.8 个月时，p53(-)组的 OS 和 BCSS 均高于 p53(+)组。p53(-)组的 5 年 OS 为 95.4%，p53(+)组为 92.1%（p=0.005）。p53(-)组的 BCSS 为 96.2%，p53(+)组为 93%（p=0.008）。
与低表达 p53 相比，免疫组化检测到的 p53 高表达与降低的 OS 和 BCSS 强烈且显著相关，这表明 p53 可能是接受 NAC 的 HR 阳性、HER2 阴性乳腺癌患者的一个强有力的预后因素。
